IT IS THE THIRD COVID-19 VACCINE EXPERIMENT TO TAKE PLACE AT THE UCHEALTH FACILITY
El Comercio de Colorado Newsroom
Researchers from the University of Colorado School of Medicine and UCHealth at the Anschutz Medical Campus are recruiting participants for another clinical trial of a new COVID-19 vaccine. Interested parties will be part of the phase 3 clinical trial for Novavax’s NVX-CoV2373 vaccine.
This is the third COVID-19 vaccine experiment to take place at the UCHealth facility. This health center continues to participate in the AstraZeneca COVID-19 vaccine trial in northern Colorado. Meanwhile, the Modern COVID-19 vaccine trial concluded at the end of October after enrolling about 180 participants.
Protein Antigen Vaccine
“CU’s world-class researchers have long excelled in bringing the latest clinical trials to our campus and we will continue to do so with COVID-19 vaccines and treatments,” said Donald M. Elliman Jr., president of the CU Medical Anschutz Campus. The phase 3 clinical trial of the Novavax vaccine is taking place in Colorado and three other locations in the US. The National Institute of Health supports these studies. Similar trials are also being carried out in Mexico. The investigational vaccine contains a protein antigen, a composition that differentiates it from the other two vaccines already approved in the US.
Participants in the study will be monitored for two years to determine the safety of the vaccine and whether they contract COVID-19. Two-thirds of study participants will receive a dose of NVX-CoV2373 21 days apart; one third will receive a placebo. These people will have to travel to the Anschutz medical campus for their appointments.The emphasis of Novavax’s phase 3 trial is on demonstrating the safety and efficacy of the vaccine in people who are at increased risk of contracting and becoming ill from COVID-19. UCHealth will also recruit people in higher risk groups, including the Hispanic, African American and Native American population, along with those 65 and older.
Anyone who is interested in participating can send an email
You may also like: